



郑宰愿

Associate

TEL +82-2-316-7241
FAX +82-2-756-6226
E-MAIL jwchung@shinkim.com

Mr. Jaewon Chung is an associate at Shin & Kim, mainly practicing in the areas of overseas investments, mergers and acquisitions (M&A), private equity funds (PEF), corporate governance, corporate restructuring, and other corporate law matters.

工作经历

2020-Present	Shin & Kim LLC
2025-2026	Covington & Burling LLP (Palo Alto Office) Global Visiting Lawyer
2024-2025	Administrative Secretary of the Finance Research Forum
2022	Secondment in Samsung Biologics

主要业绩

M&A & Investments

- IMM PE's full exit from Genuone Sciences
- Acquisition of controlling interest in TIRA YUTECH by LS Electric and JKL Partners
- Sale of controlling interest and tender offer for Lutronic
- Helios PE's sale of controlling interest in ISC and new share subscription
- Excelsior PE's acquisition of controlling interest in CytoGen and subscription of new shares and convertible bonds
- SKC's spin-off of its PET film business and sale of its stake

- Acquisition of Changsung Softgel by CVC Technologies Inc. in Taiwan
- OCI's acquisition of controlling interest in Bukwang Pharmaceutical
- Establishment of STAC, a joint venture (JV) between SK Geocentric and Tokuyama in Japan

Corporate restructuring including mergers, spin-offs, and comprehensive share exchanges

- SK Networks' spin-off of Speedmate business division and Trading business division
- Tender offer and comprehensive share exchange of SK Networks' stake in SK Rent-a-Car
- Spin-off of Kolmar Pharma, and share exchange of grants and merger of Genuone Sciences with Kolmar Pharma
- SK E&S's tender offer for a stake in Pusan City Gas, share exchange of grants and delisting
- SK Telecom's spin-off of TMap Mobility business unit

Bio-healthcare

- Preparation and review of contracts, including collaborative research agreements, license agreements, sales agreements, clinical trial outsourcing agreements, manufacturing consignment agreements, exclusive distribution agreements, and overseas investment agreements for pharmaceutical companies, medical device companies, biotechnology companies, CROs, etc.
- Advice on economic benefits (rebates) and other compliance matters
- Advice on business structure using a management service organization (MSO)
- Advice on large domestic hospitals and genetic testing organizations on the Medical Service Act, the Bioethics Act, the Act on Decisions on Life-sustaining Treatment, etc.

教育背景

2020-2022	Seoul National University, Graduate School of Law (Ph.D. coursework completed, Corporate Law/Commercial Law)
2017-2020	Seoul National University, School of Law (J.D., 2020)
2010-2014	Seoul National University, College of Business Administration (B.A., 2014)

资格

2020	Admitted to bar, Korea
------	------------------------

语言

Korean, English

主要活动

Research Paper/Publications/Report

- Digital Finance Law – Part III: Specific Issues: Individual Statutes, Chapter 06: Other Digital Finance-Related Laws (co-author, Parkyoungsa, 2026)
- Reform Proposals for Going-Private and Freeze-Out Transactions, Commercial Law Review, Vol. 44, No. 2 (Korean Commercial Law Association, 2025)
- Private Ordering of Corporate Governance and Its Limitations: Focusing on Recent Amendments to the Delaware General Corporation Law, Korean Commercial Law Association, Vo.43, No.3, November 2024
- Research on Corporate Governance with Global Consistency, Seoul National University Law Research Institute (Co-authored, commissioned by Ministry of Justice, 2024)
- The Challenges of State-Owned Enterprises in the Era of ESG -Balancing public values and efficiency, Korean Journal of Public Enterprise, Vol.22, No.1, June 2022 (Co-authored)

Presentation

- Private Ordering of Corporate Governance and Its Limitations, Finance Research Forum, 191st Financial Law Research Association, December 28, 2024